MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, ORKA had $25,857K increase in cash & cash equivalents over the period. -$21,701K in free cash flow.

Cash Flow Overview

Change in Cash
$25,857K
Free Cash flow
-$21,701K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-30,277 -45,573
Stock-based compensation expense
10,165 9,960
Non-cash interest expense
-0
Net accretion of premiums and discounts on marketable securities
1,040 3,300
Non-cash lease expense
132 187
Depreciation expense
20 35
Prepaid expenses and other current assets
2,402 765
Subscription receivable
-0
Other non-current assets
0 60
Accrued interest payable, related party
-0
Accounts payable
-2,456 1,202
Accrued expenses and other current liabilities
4,806 232
Operating lease liability
-439 -29
Related party accounts payable and other current liabilities
-111 -5,903
Net cash used in operating activities
-21,602 -44,014
Purchases of property and equipment
99 47
Purchases of marketable securities
267,683 152,289
Proceeds from maturities of marketable securities
145,333 200,062
Net cash used in investing activities
-122,449 47,726
Proceeds from issuance of notes payable to related party, net of issuance costs paid
-0
Proceeds from issuance of pre-merger oruka series a preferred stock, net of issuance costs paid
-0
Proceeds from the pipe financings, net
169,908 -
Proceeds from issuance of common stock
0 109
Payment of deferred offering costs
-0
Net cash provided by financing activities
169,908 109
Net increase in cash and cash equivalents
25,857 3,821
Cash and cash equivalents at beginning of period
61,575 -
Cash and cash equivalents at end of period
91,253 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Oruka Therapeutics, Inc. (ORKA)

Oruka Therapeutics, Inc. (ORKA)